July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Characterization of SHP639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Author Affiliations & Notes
  • Iok-Hou Pang
    Pharmaceutical Sciences, University of North Texas Health Science Center, Fort Worth, Texas, United States
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • J Cameron Millar
    North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Serene T Josiah
    Shire, Lexington, Massachusetts, United States
  • Anneli Savinainen
    Shire, Lexington, Massachusetts, United States
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2713. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Iok-Hou Pang, J Cameron Millar, Serene T Josiah, Anneli Savinainen; Characterization of SHP639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2713.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Natriuretic peptide receptor type B (NPR-B) agonists, such as C-type natriuretic peptide (CNP), lower intraocular pressure (IOP) in animal models when injected intraocularly. SHP639 is a topical 9-amino acid, synthetic, CNP analog in Phase 1 development for the treatment of glaucoma and ocular hypertension. We assessed the effects of SHP639 on mouse IOP and aqueous humor (AH) dynamics (AH outflow, AH formation and episcleral venous pressure) after topical ocular administration.

Methods : Ligand binding assays of SHP639 to 89 receptors and transporters were conducted by NovaScreen. NPR-B activation was evaluated by cyclic GMP production in cultured transformed human trabecular meshwork cells (GTM-3 cells). Conscious mouse IOP measurements were performed with a TonoLab® rebound tonometer. Mouse AH dynamics were evaluated by an in vivo constant-flow infusion method.

Results : At 10 µM, SHP639 inhibited ligand binding by >50% in 2 of the 89 receptors and transporters tested. SHP639 interacted with the type 2 angiotensin (AT2) receptor (IC50 = 8 µM) and the cholecystokinin A (CCK-A or CCK1) receptor (IC50 = 26 µM). In GTM-3 cells, SHP639 potently and efficaciously activated NPR-B with an EC50 of 61 ± 11 nM (mean ± SD, n = 17) and an Emax of 106 ± 11% (similar to the Emax of CNP, which defined 100%). SHP639 activated NPR-A with an EC50 of 2179 ± 670 nM (36 times more potent for NPR-B than for NPR-A). Topical ocular administration (5 μl) of SHP639 significantly lowered IOP in a dose-dependent manner: –12.1%, –21.1% and –36.1% for the 0.1%, 0.3% and 0.6% doses respectively (p<0.05 for all SHP639 doses vs. vehicle at each time point). Duration of action was >6 h and the maximum effects were observed at 2 h after topical ocular administration for all doses. At 2 h, 0.6% SHP639 significantly increased outflow facility (+155.8%, Figure), and decreased AH flow rate (–41.0%), uveoscleral outflow rate (–52.6%) and episcleral venous pressure (–31.5%; p<0.05 for all parameters SHP639 vs. vehicle). No adverse effects were observed in the SHP639-treated mice.

Conclusions : SHP639 is a selective NPR-B agonist and an efficacious topical IOP-lowering agent. Its mechanism of action has a unique combination of reducing aqueous production and increasing outflow, both of which contribute to the IOP-lowering effect.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Figure. 0.6% SHP639 increased outflow facility in mice

Figure. 0.6% SHP639 increased outflow facility in mice

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×